LKT Laboratories, Inc.

Deferasirox

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID D1621
CAS No. 201530-41-8
Chemical Name 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]- benzoic Acid

Synonym ICL670A, CGP 72 670

Formula $C_{21}H_{15}N_3O_4$
Formula Wt. 373.63
Melting Point
Purity ≥98%
Solubility



Bulk quanitites available upon request

Product ID	Size
D1621	25 mg
D1621	100 mg
D1621	250 mg

Store Temp Ambient
Ship Temp Ambient

Description Deferasirox is an iron chelator commonly used to treat iron-overload disease. Deferasirox also displays both neuroprotective and chemotherapeutic benefit as well. This compound exhibits neuroprotective activity in both in vitro and in vivo models of stroke/ischemia conditions. In vitro, deferasirox increases expression of metastasis suppressing genes, p21, caspase-3, and PARP and decreases levels of cyclin D1 and activity of NF-κB. The ability of deferasirox to inhibit iron uptake decreases tumor growth in animal models of cancer.

References

Vazana-Barad L, Granot G, Mor-Tzuntz R, et al. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk Lymphoma. 2013 Apr;54(4):851-9. PMID: 23020673.

Lui GY, Obeidy P, Ford SJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2013 Jan;83(1):179-90. PMID: 23074173.

Zhao Y, Rempe DA. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab. 2011 Jun;31 (6):1412-23. PMID: 21245873.

Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010 Aug;95(8):1308-16. PMID: 20534700.

Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther. 2007 Oct;29(10):2154-66. PMID: 18042472.